AEON
AEON Biopharma Inc - Class A (AEON)
Healthcare • NYSE MKT • $0.18-6.53%
- Symbol
- AEON
- Exchange
- NYSE MKT
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $0.18
- Daily Change
- -6.53%
- Market Cap
- $13.44M
- Trailing P/E
- N/A
- Forward P/E
- -1.10
- 52W High
- $1.45
- 52W Low
- $0.22
- Analyst Target
- $3.53
- Dividend Yield
- N/A
- Beta
- 0.64
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine. It also develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.
Company websiteResearch AEON on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.